Journal article
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required. Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clinical studies …
Authors
Shouksmith AE; Shah F; Grimard ML; Gawel JM; Raouf YS; Geletu M; Berger-Becvar A; de Araujo ED; Luchman HA; Heaton WL
Journal
Journal of Medicinal Chemistry, Vol. 62, No. 5, pp. 2651–2665
Publisher
American Chemical Society (ACS)
Publication Date
March 14, 2019
DOI
10.1021/acs.jmedchem.8b01957
ISSN
0022-2623